Guanfacine - Revision history

MDElliottMD: parser-claude housekeeping, stimulants to psychostimulants per house rule

2026-05-23T06:16:32Z

parser-claude housekeeping, stimulants to psychostimulants per house rule

← Older revision		Revision as of 06:16, 23 May 2026
Line 4:		Line 4:
	\| structure =		\| structure =
	\| classes = [[:Category:Alpha-2 adrenergic agonists\|Alpha-2 adrenergic agonist]], [[:Category:ADHD medicines\|ADHD medicine]], [[:Category:Antihypertensives\|Antihypertensive (historical)]]		\| classes = [[:Category:Alpha-2 adrenergic agonists\|Alpha-2 adrenergic agonist]], [[:Category:ADHD medicines\|ADHD medicine]], [[:Category:Antihypertensives\|Antihypertensive (historical)]]
	\| uses = <vote slug="adhd-use">Attention-deficit/hyperactivity disorder (monotherapy or adjunct to ~~stimulants~~, ages 6-17)</vote>, <vote slug="tic-disorders-use">Tic disorders / Tourette syndrome (off-label)</vote>, <vote slug="opioid-withdrawal-adjunct-use">Opioid withdrawal adjunct (off-label)</vote>, <vote slug="ptsd-nightmares-use">PTSD-associated nightmares and hyperarousal (off-label, selected populations)</vote>, <vote slug="hypertension-historical-use">Hypertension (historical indication, largely supplanted by other classes)</vote>		\| uses = <vote slug="adhd-use">Attention-deficit/hyperactivity disorder (monotherapy or adjunct to psychostimulants, ages 6-17)</vote>, <vote slug="tic-disorders-use">Tic disorders / Tourette syndrome (off-label)</vote>, <vote slug="opioid-withdrawal-adjunct-use">Opioid withdrawal adjunct (off-label)</vote>, <vote slug="ptsd-nightmares-use">PTSD-associated nightmares and hyperarousal (off-label, selected populations)</vote>, <vote slug="hypertension-historical-use">Hypertension (historical indication, largely supplanted by other classes)</vote>
	\| starting_dose = Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response		\| starting_dose = Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response
	\| preparations = Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex)		\| preparations = Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex)

MDElliottMD: parser-claude: Guanfacine MedTemplate pre-fill, Top 300 #263 (stub upgrade)

2026-05-23T06:16:00Z

parser-claude: Guanfacine MedTemplate pre-fill, Top 300 #263 (stub upgrade)

← Older revision		Revision as of 06:16, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Guanfacine		\| generic = Guanfacine
	\| brand = Intuniv		\| brand = Intuniv (extended-release), Tenex (immediate-release)
	\| structure =		\| structure =
	\| classes = Alpha-2 agonist, ADHD medicine		\| classes = [[:Category:Alpha-2 adrenergic agonists\|Alpha-2 adrenergic agonist]], [[:Category:ADHD medicines\|ADHD medicine]], [[:Category:Antihypertensives\|Antihypertensive (historical)]]
	\| ~~mechanism~~ = ~~Selective alpha~~-~~2A adrenergic receptor agonist~~		\| uses = <vote slug="adhd-use">Attention-deficit/hyperactivity disorder (monotherapy or adjunct to stimulants, ages 6-17)</vote>, <vote slug="tic-disorders-use">Tic disorders / Tourette syndrome (off-label)</vote>, <vote slug="opioid-withdrawal-adjunct-use">Opioid withdrawal adjunct (off-label)</vote>, <vote slug="ptsd-nightmares-use">PTSD-associated nightmares and hyperarousal (off-label, selected populations)</vote>, <vote slug="hypertension-historical-use">Hypertension (historical indication, largely supplanted by other classes)</vote>
	\| ~~uses~~ =		\| starting_dose = Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response
	\| ~~starting_dose~~ =		\| preparations = Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex)
	\| ~~preparations~~ =		\| fda_max = 7 mg/day in children and adolescents; weight-based ceiling (~0.12 mg/kg/day) applies in smaller patients
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Gradual; full clinical effect over 2-4 weeks of titration
	\| duration =		\| duration = ~24 hours (ER formulation supports once-daily dosing)
	\| halflife =		\| halflife = ~17-18 hours (Intuniv ER); ~17 hours (immediate-release)<ref name="intuniv-label">FDA Prescribing Information, Intuniv (guanfacine extended-release), Shire/Takeda, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~58% (extended-release); ~80% (immediate-release)<ref name="intuniv-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data. Animal studies show fetal effects at maternally toxic doses; use only if benefits justify the potential risk.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Not a controlled substance, which is a meaningful contrast to the psychostimulant alternatives for ADHD<ref name="intuniv-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="guanfacine-mech-claim">Selective postsynaptic α2A-adrenergic receptor agonist. In the prefrontal cortex, α2A activation on pyramidal-neuron dendritic spines strengthens working-memory and attention-regulation circuits by closing HCN channels and reducing cyclic-AMP-driven "noise" from competing inputs. The peripheral antihypertensive effect (the historical indication) reflects α2 agonism in brainstem sympathetic outflow regions.</vote> Sedation and hypotension are the dose-limiting effects; gradual titration and bedtime or split dosing mitigate both. Abrupt discontinuation can precipitate rebound hypertension, particularly with long-standing use<ref name="intuniv-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
	~~[[Category:Alpha-2 Adrenergic Agonists]]~~		<references />

MDElliottMD: Tier 2 taxonomy consolidation: Category:Alpha-2 Agonists (for ADHD) -> Category:Alpha-2 Adrenergic Agonists

2026-05-21T18:28:27Z

Tier 2 taxonomy consolidation: Category:Alpha-2 Agonists (for ADHD) -> Category:Alpha-2 Adrenergic Agonists

← Older revision		Revision as of 18:28, 21 May 2026
Line 32:		Line 32:


	[[Category:Alpha-2 Agonists ~~(for ADHD)~~]]		[[Category:Alpha-2 Adrenergic Agonists]]

MDElliottMD: Remove Category:Psychostimulants tag (second pass after duplicate-tag situation)

2026-05-18T01:01:05Z

Remove Category:Psychostimulants tag (second pass after duplicate-tag situation)

← Older revision		Revision as of 01:01, 18 May 2026
Line 32:		Line 32:


	~~[[Category:Psychostimulants]]~~
	[[Category:Alpha-2 Agonists (for ADHD)]]		[[Category:Alpha-2 Agonists (for ADHD)]]

MDElliottMD: Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

2026-05-18T00:48:07Z

Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

← Older revision		Revision as of 00:48, 18 May 2026
Line 32:		Line 32:


	~~[[Category:Psychostimulants]]~~
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Alpha-2 Agonists (for ADHD)]]		[[Category:Alpha-2 Agonists (for ADHD)]]

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:50:44Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:50, 17 May 2026
Line 32:		Line 32:


	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Alpha-2 Agonists (for ADHD)]]		[[Category:Alpha-2 Agonists (for ADHD)]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:44:57Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:44, 17 May 2026
Line 32:		Line 32:


	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Alpha-2 Agonists (for ADHD)]]		[[Category:Alpha-2 Agonists (for ADHD)]]

MDElliottMD: Comprehensive categorization: +Alpha-2 Agonists (for ADHD)

2026-05-15T18:42:06Z

Comprehensive categorization: +Alpha-2 Agonists (for ADHD)

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Stimulants & Wake-Promoting Agents]]		[[Category:Stimulants & Wake-Promoting Agents]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
			[[Category:Alpha-2 Agonists (for ADHD)]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:55Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Stimulants & Wake-Promoting Agents]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:53Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =